Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223491 | 0.75 | AKT1 (0.37) | HDAC1HDAC6FAAHMAPK1 | |
| SCHEMBL29336456 | 0.73 | SLC6A5 (0.48) | KMT2ANOD1POLBSLC6A5MEN1 | |
| SCHEMBL24235669 | 0.73 | KMT2A (0.53) | DNM1KMT2ANOD1POLBSLC6A5 | |
| SCHEMBL9236716 | 0.73 | KMT2A (0.53) | DNM1KMT2ANOD1POLBSLC6A5 | |
| SCHEMBL9088322 | 0.73 | KMT2A (0.53) | DNM1KMT2ANOD1POLBSLC6A5 | |
| SCHEMBL22223354 | 0.72 | KMT2A (0.39) | DNM1KMT2ANOD1POLBSLC6A5 | |
| SCHEMBL23352602 | 0.72 | ITGB3 (0.42) | KMT2ASLC6A5MEN1 | |
| SCHEMBL20450528 | 0.72 | SLC6A5 (0.50) | KMT2ANOD1SLC6A5MEN1 | |
| SCHEMBL20450608 | 0.72 | SLC6A5 (0.47) | KMT2ANOD1POLBSLC6A5 | |
| SCHEMBL20450607 | 0.72 | SLC6A5 (0.47) | KMT2ANOD1POLBSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | DNM1 3093/4885KMT2A 616/4885NOD1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.